Literature DB >> 23945393

High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

Young Hak Kim1, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, Yoshitaka Yagi, Takashi Nakaoku, Michiaki Mishima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23945393     DOI： 10.1097/JTO.0b013e31829cebbb

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  15 in total

Review 1.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

2.  Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Authors:  Sai-Hong Ignatius Ou; Karen R Sommers; Michele C Azada; Edward B Garon
Journal:  Oncologist       Date:  2015-01-07

Review 3.  ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.

Authors:  Ivana Sullivan; David Planchard
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 4.  Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.

Authors:  Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-05-01       Impact factor: 12.531

5.  Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Authors:  Justin F Gainor; Carol A Sherman; Kathryn Willoughby; Jennifer Logan; Elizabeth Kennedy; Priscilla K Brastianos; Andrew S Chi; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

6.  Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.

Authors:  Hitomi Ajimizu; Young Hak Kim; Michiaki Mishima
Journal:  Med Oncol       Date:  2015-01-03       Impact factor: 3.064

Review 7.  Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.

Authors:  M Drizou; E A Kotteas; N Syrigos
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

Review 8.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

Review 9.  Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.

Authors:  Rimas V Lukas; Maciej S Lesniak; Ravi Salgia
Journal:  CNS Oncol       Date:  2014-01

Review 10.  Oral Targeted Therapies and Central Nervous System (CNS) Metastases.

Authors:  Michael P Gabay; Scott M Wirth; Joan M Stachnik; Colleen L Overley; Katie E Long; Linda R Bressler; John L Villano
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.